Abstract
IGF-I is a potent fibrogenic growth factor that stimulates proliferation of intestinal smooth muscle cells and increases synthesis of collagen and IGF-I-binding proteins by the cells. These processes contribute to intestinal fibrosis that develops in patients with Crohn's disease and in Lewis-strain rats with experimental Crohn's disease. The aim of this study was to determine which early docking proteins are associated with IGF-I receptor signal transduction and which transduction pathway is involved in IGF-I-mediated gene regulation in intestinal smooth muscle cells. Primary cultures of smooth muscle cells isolated from the muscularis externa of the distal colon of Lewis rats were treated with IGF-I (100 ng/ml). Immunoprecipitation studies demonstrated that IGF-I stimulation resulted in tyrosine phosphorylation of IRS-1, IRS-2, and Shc. Coimmunoprecipitation demonstrated a close association between the IGF-I receptor and these three early docking proteins. Concurrent treatment with the MAPK inhibitor PD98059 (10 microM) resulted in an inhibition of the IGF-I-mediated increase in IGFBP-5 and collagen alpha(1)(I) mRNAs, while concurrent treatment with the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin (100 nM) had no effect. In additional experiments, cells were transiently transfected with adenoviral vectors dominantly expressing inactive mutant Akt or constitutively expressing wild-type Akt. In both cases, the IGF-I-mediated increase in collagen I protein did not differ from that observed in control cultures that had been transfected with an adenoviral vector carrying the LacZ reporter gene. These results suggest that the MAPK pathway is key to IGF-I-mediated gene regulation in intestinal smooth muscle cells, whereas data do not suggest a role for the Akt-dependent pathway in our system.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adaptor Proteins, Signal Transducing*
-
Adaptor Proteins, Vesicular Transport / metabolism
-
Animals
-
Cells, Cultured
-
Collagen Type I / genetics
-
Collagen Type I / metabolism*
-
Crohn Disease / metabolism*
-
Crohn Disease / pathology
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / pharmacology
-
Female
-
Flavonoids / pharmacology
-
Insulin Receptor Substrate Proteins
-
Insulin-Like Growth Factor Binding Protein 5 / genetics
-
Insulin-Like Growth Factor Binding Protein 5 / metabolism*
-
Insulin-Like Growth Factor I / administration & dosage
-
Insulin-Like Growth Factor I / pharmacology
-
Insulin-Like Growth Factor I / physiology*
-
Intestinal Mucosa / metabolism*
-
Intestines / drug effects
-
Intracellular Signaling Peptides and Proteins
-
Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
Mitogen-Activated Protein Kinases / metabolism*
-
Myocytes, Smooth Muscle / drug effects
-
Myocytes, Smooth Muscle / metabolism*
-
Phosphoproteins / metabolism
-
Phosphorylation / drug effects
-
RNA, Messenger / antagonists & inhibitors
-
RNA, Messenger / metabolism
-
Rats
-
Rats, Inbred Lew
-
Receptor, IGF Type 1 / metabolism
-
Shc Signaling Adaptor Proteins
-
Src Homology 2 Domain-Containing, Transforming Protein 1
-
Time Factors
-
Tyrosine / metabolism
Substances
-
Adaptor Proteins, Signal Transducing
-
Adaptor Proteins, Vesicular Transport
-
Collagen Type I
-
Enzyme Inhibitors
-
Flavonoids
-
Insulin Receptor Substrate Proteins
-
Insulin-Like Growth Factor Binding Protein 5
-
Intracellular Signaling Peptides and Proteins
-
Irs1 protein, rat
-
Irs2 protein, rat
-
Phosphoproteins
-
RNA, Messenger
-
Shc Signaling Adaptor Proteins
-
Shc1 protein, rat
-
Src Homology 2 Domain-Containing, Transforming Protein 1
-
Tyrosine
-
Insulin-Like Growth Factor I
-
Receptor, IGF Type 1
-
Mitogen-Activated Protein Kinases
-
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one